2009
Aripiprazole monotherapy in acute mania: 12-week randomised placebo- and haloperidol-controlled study
Young A, Oren D, Lowy A, McQuade R, Marcus R, Carson W, Spiller N, Torbeyns A, Sanchez R. Aripiprazole monotherapy in acute mania: 12-week randomised placebo- and haloperidol-controlled study. The British Journal Of Psychiatry 2009, 194: 40-48. PMID: 19118324, DOI: 10.1192/bjp.bp.108.049965.Peer-Reviewed Original ResearchConceptsWeek 12Young Mania Rating Scale (YMRS) total scoreDouble-blind aripiprazoleHaloperidol-treated patientsTolerability of aripiprazoleExtrapyramidal adverse eventsScale total scoreMasked treatmentAdverse eventsClinical improvementAcute maniaAripiprazole monotherapyBipolar maniaMixed episodesEffective therapyEffect therapyAripiprazoleAdditional weeksHaloperidolWeek 3PlaceboPatientsTotal scoreTherapyMania
2008
A Randomized, Double-Blind, Placebo-Controlled Tolerability Study of Intramuscular Aripiprazole in Acutely Agitated Patients With Alzheimer's, Vascular, or Mixed Dementia
Rappaport S, Marcus R, Manos G, McQuade R, Oren D. A Randomized, Double-Blind, Placebo-Controlled Tolerability Study of Intramuscular Aripiprazole in Acutely Agitated Patients With Alzheimer's, Vascular, or Mixed Dementia. Journal Of The American Medical Directors Association 2008, 10: 21-27. PMID: 19111849, DOI: 10.1016/j.jamda.2008.06.006.Peer-Reviewed Original ResearchConceptsAgitation-Calmness Evaluation ScaleIM aripiprazoleIM placeboMixed dementiaIntramuscular aripiprazoleDoses 2 hoursIncidence of oversedationTreatment of agitationHealthcare facilitiesPreliminary efficacy analysisAdverse event reportingNegative Syndrome ScaleLong-term careAcute agitationEfficacy analysisTolerability studyPlaceboPEC scoresAripiprazoleGreater incidenceSyndrome ScaleGreater efficacyPatientsVital signsDementia
2007
Efficacy and Safety of Oral Aripiprazole Compared with Haloperidol in Patients Transitioning from Acute Treatment with Intramuscular Formulations
DANIEL D, CURRIER G, ZIMBROFF D, ALLEN M, OREN D, MANOS G, MCQUADE R, PIKALOV A, CRANDALL D. Efficacy and Safety of Oral Aripiprazole Compared with Haloperidol in Patients Transitioning from Acute Treatment with Intramuscular Formulations. Journal Of Psychiatric Practice 2007, 13: 170-177. PMID: 17522560, DOI: 10.1097/01.pra.0000271658.86845.81.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAdministration, OralAdolescentAdultAgedAntipsychotic AgentsAripiprazoleDouble-Blind MethodDyskinesia, Drug-InducedFemaleHaloperidolHumansInjections, IntramuscularMaleMiddle AgedPiperazinesPsychiatric Status Rating ScalesPsychomotor AgitationPsychotic DisordersQuinolonesSchizophreniaConceptsOral aripiprazoleOral formulationHaloperidol IMOral phaseIntramuscular formulationEfficacy measuresSchizoaffective disorderExtrapyramidal symptom-related adverse eventsPrimary efficacy measureStudy days 1Negative Syndrome ScalePlacebo IMAcute treatmentAdverse eventsGood tolerabilityClinical statusMean changePEC scoresPatientsDay 1HaloperidolAripiprazoleSyndrome ScaleInitial benefitComponent scoresIntramuscular Aripiprazole in the Control of Agitation
CURRIER G, CITROME L, ZIMBROFF D, OREN D, MANOS G, MCQUADE R, PIKALOV A, CRANDALL D. Intramuscular Aripiprazole in the Control of Agitation. Journal Of Psychiatric Practice 2007, 13: 159-169. PMID: 17522559, DOI: 10.1097/01.pra.0000271657.09717.e2.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntipsychotic AgentsAripiprazoleArousalBipolar DisorderDose-Response Relationship, DrugDouble-Blind MethodDrug Administration ScheduleFemaleHaloperidolHumansHypnotics and SedativesInjections, IntramuscularLorazepamMaleMiddle AgedMulticenter Studies as TopicPiperazinesPsychiatric Status Rating ScalesPsychomotor AgitationQuinolonesRandomized Controlled Trials as TopicSchizophreniaSchizophrenic PsychologyTreatment OutcomeConceptsBipolar I disorderPEC scoresAripiprazole injectionI disordersBaseline agitationSecond injectionNegative Syndrome Scale Excited ComponentBaseline levelsSecondary analysisControl of agitationImportant clinical issueIntramuscular aripiprazoleAnalysis 3Clinical trialsAgitation symptomsMean changeNonspecific sedationPatientsBaseline scoresClinical issuesPlaceboAnalysis 2Analysis 1Study periodSchizophreniaManagement of Acute Agitation in Patients With Bipolar Disorder
Zimbroff D, Marcus R, Manos G, Stock E, McQuade R, Auby P, Oren D. Management of Acute Agitation in Patients With Bipolar Disorder. Journal Of Clinical Psychopharmacology 2007, 27: 171-176. PMID: 17414241, DOI: 10.1097/jcp.0b13e318033bd5e.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAdultAnti-Anxiety AgentsAntipsychotic AgentsAripiprazoleBipolar DisorderDisorders of Excessive SomnolenceDizzinessDose-Response Relationship, DrugDouble-Blind MethodDrug Administration ScheduleFemaleHeadacheHumansInjections, IntramuscularLorazepamMaleNauseaPatient DropoutsPiperazinesPsychomotor AgitationQuinolonesSleep Initiation and Maintenance DisordersTreatment OutcomeVomitingConceptsIM aripiprazoleIM placeboIM lorazepamAcute agitationActive treatmentEfficacy measuresFirst injectionBipolar disorderDouble-blind multicenter studyTreatment of agitationPrimary efficacy measureRisk-benefit profileComponent scoresAripiprazole dosesIntramuscular aripiprazoleOral aripiprazoleMixed episodesMulticenter studySafety profileEfficacy parametersLower incidenceMean changePlaceboAripiprazolePatients
2006
Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol
Andrezina R, Josiassen R, Marcus R, Oren D, Manos G, Stock E, Carson W, Iwamoto T. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol. Psychopharmacology 2006, 188: 281-292. PMID: 16953381, DOI: 10.1007/s00213-006-0541-x.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAdministration, OralAdolescentAdultAnti-Dyskinesia AgentsAntipsychotic AgentsAripiprazoleBasal Ganglia DiseasesBenzodiazepinesBlood GlucoseDouble-Blind MethodDrug Therapy, CombinationFemaleHaloperidolHumansInjections, IntramuscularMalePiperazinesPsychomotor AgitationPsychotic DisordersQuinolonesSchizophreniaTime FactorsTreatment OutcomeWithholding TreatmentConceptsIM aripiprazoleIM haloperidolAcute agitationIntramuscular aripiprazoleEfficacy measuresSchizoaffective disorderExtrapyramidal symptom-related adverse eventsPlacebo-controlled studySecondary efficacy measuresPercentage of patientsPlacebo-controlled comparisonPrimary efficacy measureIM placeboIntramuscular haloperidolAdverse eventsMethodsFour hundredThird injectionMean changePlaceboEffective treatmentHaloperidolPatientsAripiprazoleConclusionThese resultsMean number
2003
Regional Brain Metabolic Correlates of α-Methylparatyrosine–Induced Depressive Symptoms: Implications for the Neural Circuitry of Depression
Bremner JD, Vythilingam M, Ng CK, Vermetten E, Nazeer A, Oren DA, Berman RM, Charney DS. Regional Brain Metabolic Correlates of α-Methylparatyrosine–Induced Depressive Symptoms: Implications for the Neural Circuitry of Depression. JAMA 2003, 289: 3125-3134. PMID: 12813118, PMCID: PMC3233764, DOI: 10.1001/jama.289.23.3125.Peer-Reviewed Original ResearchConceptsNorepinephrine reuptake inhibitorsSelective serotonin reuptake inhibitorsBrain metabolic correlatesDepressive symptomsDorsolateral prefrontal cortexReuptake inhibitorsBrain metabolismMetabolic correlatesPrefrontal cortexPsychiatric research unitDouble-blind trialPositron emission tomography (PET) measurementsDepletion of norepinephrineSerotonin reuptake inhibitorsDifferent neurochemical systemsCommon brain circuitryAMPT administrationInitial medicationPlacebo administrationLimbic areasAcute decreaseDepressed patientsCortical areasPatientsDay 3
2002
Lack of a therapeutic effect of a 2-week sub-threshold transcranial magnetic stimulation course for treatment-resistant depression
Boutros NN, Gueorguieva R, Hoffman RE, Oren DA, Feingold A, Berman RM. Lack of a therapeutic effect of a 2-week sub-threshold transcranial magnetic stimulation course for treatment-resistant depression. Psychiatry Research 2002, 113: 245-254. PMID: 12559481, DOI: 10.1016/s0165-1781(02)00267-6.Peer-Reviewed Original ResearchConceptsRepetitive transcranial magnetic stimulationTreatment-resistant depressed patientsDepressed patientsTherapeutic effectActive repetitive transcranial magnetic stimulationStimulation parametersTreatment-resistant depressionDouble-blind designTranscranial magnetic stimulationLeft prefrontal cortexSham groupMagnetic stimulationStimulation courseRTMS stimulationPatientsSystematic followThreshold stimulationPrefrontal cortexFollowPre-set criteriaSignificant differencesStimulationWork daysWeeksConsecutive work daysMonoamine depletion in unmedicated depressed subjects
Berman RM, Sanacora G, Anand A, Roach LM, Fasula MK, Finkelstein CO, Wachen RM, Oren DA, Heninger GR, Charney DS. Monoamine depletion in unmedicated depressed subjects. Biological Psychiatry 2002, 51: 469-473. PMID: 11922881, DOI: 10.1016/s0006-3223(01)01285-9.Peer-Reviewed Original ResearchConceptsUnmedicated depressed subjectsDepressed subjectsCatecholamine depletionDepressed patientsMean Hamilton Depression Rating Scale scoreHamilton Depression Rating Scale scoresRandom-order crossover studyDepression Rating Scale scoresRating Scale scoresDepressed control subjectsSignificant mood changesMonoamine depletionCrossover studyCatecholamine functionControl subjectsMonoamine functionMonoamine systemsStudy daysClinical depressionScale scoreMood changesPatientsIndoleamineGreater increaseIndirect mechanisms
2000
No effect of light on basal glucagon levels in winter seasonal depressives and comparison subjects
Oren D, Berman R, Anand A, Charney D. No effect of light on basal glucagon levels in winter seasonal depressives and comparison subjects. Psychiatry Research 2000, 94: 263-266. PMID: 10889291, DOI: 10.1016/s0165-1781(00)00158-x.Peer-Reviewed Original ResearchAntidepressant effects of ketamine in depressed patients
Berman R, Cappiello A, Anand A, Oren D, Heninger G, Charney D, Krystal J. Antidepressant effects of ketamine in depressed patients. Biological Psychiatry 2000, 47: 351-354. PMID: 10686270, DOI: 10.1016/s0006-3223(99)00230-9.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntidepressive AgentsDepressive Disorder, MajorDose-Response Relationship, DrugDouble-Blind MethodExcitatory Amino Acid AntagonistsFemaleGlutamic AcidHumansInjections, IntravenousKetamineMaleMiddle AgedPsychiatric Status Rating ScalesReceptors, N-Methyl-D-AspartateSeverity of Illness IndexConceptsMajor depressionN-methyl-D-aspartate receptor antagonistBrain glutamate systemDouble-blind trialDouble-blind conditionsTreatment of depressionMechanism of actionPlacebo infusionAntidepressant effectsIntravenous treatmentSingle doseReceptor antagonistDepressed patientsGlutamate systemDepressive symptomsPreclinical researchKetamine hydrochlorideDepressionPotential roleTest dayTreatment effectsPatientsKetamineSaline solutionTreatment
1998
Carbon monoxide poisoning and treatment with hyperbaric oxygen in the subacute phase
Coric V, Oren D, Wolkenberg F, Kravitz R. Carbon monoxide poisoning and treatment with hyperbaric oxygen in the subacute phase. Journal Of Neurology Neurosurgery & Psychiatry 1998, 65: 245. PMID: 9703180, PMCID: PMC2170185, DOI: 10.1136/jnnp.65.2.245.Peer-Reviewed Original ResearchConceptsHyperbaric oxygenCarbon monoxide poisoningPatient underwent treatmentAnterograde memory lossCarbon monoxide intoxicationCarbon monoxide exposureAcute confusionNeuropsychiatric functionSubacute phaseSymptom reliefUnderwent treatmentClinical findingsNormobaric oxygenImmediate treatmentBrain injuryTherapeutic windowNeuropsychological testingMatter of debateMemory lossPartial retrogradeTreatmentMonthsPoisoningNormobaricPatients
1996
Circadian profiles of cortisol, prolactin, and thyrotropin in seasonal affective disorder
Oren D, Levendosky A, Kasper S, Duncan C, Rosenthal N. Circadian profiles of cortisol, prolactin, and thyrotropin in seasonal affective disorder. Biological Psychiatry 1996, 39: 157-170. PMID: 8837977, DOI: 10.1016/0006-3223(95)00079-8.Peer-Reviewed Original Research
1995
The phototherapy light visor: more to it than meets the eye
Teicher M, Glod C, Oren D, Schwartz P, Luetke C, Brown C, Rosenthal N. The phototherapy light visor: more to it than meets the eye. American Journal Of Psychiatry 1995, 152: 1197-1202. PMID: 7625470, DOI: 10.1176/ajp.152.8.1197.Peer-Reviewed Original ResearchConceptsAtypical depressive symptomsLight visorDepressive symptomsHamilton Depression Scale scoresHamilton Depression Rating ScaleBaseline depression scoresDepression Rating ScaleDepression Scale scoresFull clinical responseModerate response rateSeasonal affective disorderDim red lightClinical responseTherapeutic responseTreatment periodEffective treatmentDepression scoresPatientsResponse rateScale scoreAffective disordersRating ScaleBright white lightSignificant differencesSymptoms
1994
A controlled trial of cyanocobalamin (Vitamin B12) in the treatment of winter seasonal affective disorder
Oren D, Teicher M, Schwartz P, Glod C, Turner E, Ito Y, Sedway J, Rosenthal N, Wehr T. A controlled trial of cyanocobalamin (Vitamin B12) in the treatment of winter seasonal affective disorder. Journal Of Affective Disorders 1994, 32: 197-200. PMID: 7852661, DOI: 10.1016/0165-0327(94)90018-3.Peer-Reviewed Original ResearchConceptsSeasonal affective disorderWinter seasonal affective disorderAffective disordersEffective short-term treatmentWeekly outpatient visitsShort-term treatmentSIGH-SAD scoresPlacebo washoutAntidepressant efficacyOutpatient visitsWashout periodEffective treatmentSame scheduleVitamin B12SAD patientsSignificant differencesTreatmentPatientsWeeksDisordersCyanocobalaminRandom assignmentPlaceboTrialsVisitsPlatelet [3H]paroxetine binding, 5-HT-stimulated Ca2+ response, and 5-HT content in winter seasonal affective disorder
Ozaki N, Rosenthal N, Mazzola P, Chiueh C, Hardin T, Garcia-Borreguero D, Schwartz P, Turner E, Oren D, Murphy D. Platelet [3H]paroxetine binding, 5-HT-stimulated Ca2+ response, and 5-HT content in winter seasonal affective disorder. Biological Psychiatry 1994, 36: 458-466. PMID: 7811842, DOI: 10.1016/0006-3223(94)90641-6.Peer-Reviewed Original ResearchConceptsSeasonal affective disorderWinter seasonal affective disorderSAD patientsAffective disordersBrain serotonergic systemSerotonergic measuresSerotonergic abnormalitiesSerotonergic functionDensity-dependent subpopulationsPlatelet turnoverSerotonergic systemPatientsReceptor functionNeurotransmitter aminesTherapy conditionsHigher BmaxLight plateletsPlateletsDisordersPresent studyHeavy plateletsCa2SerotoninA Controlled Trial of Levodopa Plus Carbidopa in the Treatment of Winter Seasonal Affective Disorder
OREN D, MOUL D, SCHWARTZ P, WEHR T, ROSENTHAL N. A Controlled Trial of Levodopa Plus Carbidopa in the Treatment of Winter Seasonal Affective Disorder. Journal Of Clinical Psychopharmacology 1994, 14: 196-200. PMID: 8027416, DOI: 10.1097/00004714-199406000-00007.Peer-Reviewed Original ResearchConceptsSeasonal affective disorderWinter seasonal affective disorderDopaminergic deficiencyAffective disordersItem Hamilton Rating ScaleEfficacy of levodopaUse of levodopaWeekly outpatient visitsHamilton Rating ScalePlacebo washoutAntidepressant efficacyOutpatient visitsWashout periodRate of responseDepression scoresPatientsLevodopaPlaceboCarbidopaRating ScaleIdentical scheduleSAD patientsTreatmentWeeksDisordersExposure to ambient light in patients with winter seasonal affective disorder
Oren D, Moul D, Schwartz P, Brown C, Yamada E, Rosenthal N. Exposure to ambient light in patients with winter seasonal affective disorder. American Journal Of Psychiatry 1994, 151: 591-593. PMID: 8147459, DOI: 10.1176/ajp.151.4.591.Peer-Reviewed Original ResearchConceptsWinter seasonal affective disorderSeasonal affective disorderAffective disordersSeverity of depressionNormal comparison subjectsMorning light exposureNormal subjectsComparison subjectsGreater severityPatientsDepressionDisordersExposure profilesSeverityExposureLight exposureSubjectsShort photoperiodOutpatientsLight monitorWeeksHigh titers of anti‐epstein‐barr virus DNA polymerase are found in patients with severe fatiguing illness
Natelson B, Ye N, Moul D, Jenkins F, Oren D, Tapp W, Cheng Y. High titers of anti‐epstein‐barr virus DNA polymerase are found in patients with severe fatiguing illness. Journal Of Medical Virology 1994, 42: 42-46. PMID: 8308519, DOI: 10.1002/jmv.1890420109.Peer-Reviewed Original ResearchConceptsChronic fatigue syndromeEpstein-Barr virusEBV DNA polymeraseSeasonal affective disorderAbnormal testsFatiguing illnessesSAD patientsSubset of patientsAbnormal titersCFS patientsSymptomatic patientsFatigue syndromePatient groupTreatment trialsHealthy controlsPatientsNormal rangeAffective disordersDisease severityUseful markerHigh titersAge rangeSocioeconomic classAntibodiesIllness
1993
Effects of phototherapy on electrooculographic ratio in winter seasonal affective disorder
Ozaki N, Rosenthal N, Moul D, Schwartz P, Oren D. Effects of phototherapy on electrooculographic ratio in winter seasonal affective disorder. Psychiatry Research 1993, 49: 99-107. PMID: 8153191, DOI: 10.1016/0165-1781(93)90098-2.Peer-Reviewed Original ResearchConceptsSeasonal affective disorderControl subjectsLight therapyEOG ratiosSAD patientsAffective disordersEffect of phototherapyNormal control subjectsWinter seasonal affective disorderRetinal abnormalitiesPatientsConfounding factorsEOG testingTherapyDisordersSubjectsTest variabilityOutpatientsAbnormalitiesPhototherapy